Navigating the IP minefield
When it comes to diabetes devices there are a host of issues that wannabes must navigate. The least talked about and perhaps the most difficult area to navigate is the intellectual property minefield. Next to having an FDA approved product and talented management team a company’s intellectual property portfolio becomes a valuable and useful asset.
To fully appreciate just how valuable look no further than the now defunct Cozmo insulin pump. Way back in the day when Medtronic ruled the insulin pump world the main competition was Animas, then a private company and the Cozmo owned by Smith’s . . .
This content is restricted to subscribers. Please subscribe.
Already have an account? Please login.